{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:37:55Z","timestamp":1781023075721,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12933-016-0430-5","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T08:44:35Z","timestamp":1470991475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor \u03b4 (PPAR\u03b4): from bedside to bench"],"prefix":"10.1186","volume":"15","author":[{"given":"Wei-Ting","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juei-Tang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhih-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"issue":"25","key":"430_CR1","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","volume":"115","author":"S Boudina","year":"2007","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213\u201323.","journal-title":"Circulation"},{"key":"430_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-015-0201-8","volume":"14","author":"Y Mochizuki","year":"2015","unstructured":"Mochizuki Y, Tanaka H, Matsumoto K, et al. Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus. Cardiovasc Diabetol. 2015;14:37.","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"430_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2011.01.015","volume":"24","author":"V Mor-Avi","year":"2011","unstructured":"Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE\/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24(3):277\u2013313.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"430_CR4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/labinvest.2011.45","volume":"91","author":"Y Maejima","year":"2011","unstructured":"Maejima Y, Okada H, Haraguchi G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011;91(6):932\u201344.","journal-title":"Lab Invest"},{"key":"430_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1475-2840-13-91","volume":"13","author":"CH Chang","year":"2014","unstructured":"Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS. Different\u00a0angiotensin\u00a0receptor\u00a0blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2014;13:91.","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"430_CR6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1139\/cjpp-2014-0416","volume":"93","author":"WW Wang","year":"2015","unstructured":"Wang WW, Zhang FL, Chen JH, et al. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3\u00a0K-Akt-eNOS pathways in spontaneously hypertensive rats. Can J Physiol Pharmacol. 2015;93(8):657\u201365.","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"430_CR7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/2193-1801-2-198","volume":"2","author":"M Dessi","year":"2013","unstructured":"Dessi M, Madeddu C, Piras A, et al. Long-term, up to 18\u00a0months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2(1):198.","journal-title":"Springerplus."},{"issue":"9","key":"430_CR8","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1097\/HJH.0b013e32832d8785","volume":"27","author":"Y Mizuguchi","year":"2009","unstructured":"Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T. Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging. J Hypertens. 2009;27(9):1892\u20139.","journal-title":"J Hypertens"},{"issue":"13","key":"430_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2261-13-39","volume":"5","author":"XC Zeng","year":"2013","unstructured":"Zeng XC, Li XS, Wen H. Telmisartan protects against microvascular dysfunction during myocardial ischemia\/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma. BMC Cardiovasc Disord. 2013;5(13):39.","journal-title":"BMC Cardiovasc Disord."},{"issue":"7","key":"430_CR10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","volume":"33","author":"V Sukumaran","year":"2010","unstructured":"Sukumaran V, Watanabe K, Veeraveedu PT, et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res. 2010;33(7):695\u2013702.","journal-title":"Hypertens Res"},{"issue":"7","key":"430_CR11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/hr.2009.61","volume":"32","author":"M Kawai","year":"2009","unstructured":"Kawai M, Hongo K, Komukai K, et al. Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertens Res. 2009;32(7):604\u201310.","journal-title":"Hypertens Res"},{"issue":"1\u20133","key":"430_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2009.07.026","volume":"619","author":"S Goyal","year":"2009","unstructured":"Goyal S, Arora S, Mittal R, et al. Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol. 2009;619(1\u20133):75\u201384.","journal-title":"Eur J Pharmacol"},{"key":"430_CR13","doi-asserted-by":"crossref","first-page":"245410","DOI":"10.1155\/2008\/245410","volume":"2008","author":"AC Calkin","year":"2008","unstructured":"Calkin AC, Thomas MC. PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008;2008:245410.","journal-title":"PPAR Res."},{"issue":"5","key":"430_CR14","doi-asserted-by":"crossref","first-page":"e64229","DOI":"10.1371\/journal.pone.0064229","volume":"8","author":"ZC Chen","year":"2013","unstructured":"Chen ZC, Lee KS, Chen LJ, Wang LY, Niu HS, Cheng JT. Cardiac peroxisome proliferator-activated receptor delta (PPARdelta) as a new target for increased contractility without altering heart rate. PLoS ONE. 2013;8(5):e64229.","journal-title":"PLoS ONE"},{"issue":"11","key":"430_CR15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1463-1326.2012.01601.x","volume":"14","author":"JP Wilding","year":"2012","unstructured":"Wilding JP. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab. 2012;14(11):973\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"430_CR16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cvr\/cvn172","volume":"80","author":"BC Yu","year":"2008","unstructured":"Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res. 2008;80(1):78\u201387.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"430_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.115.017472","volume":"133","author":"W Zhang","year":"2016","unstructured":"Zhang W, Qu X, Chen B, et al. Critical roles of STAT3 in \u03b2-adrenergic functions in the heart. Circulation. 2016;133(1):48\u201361.","journal-title":"Circulation"},{"key":"430_CR18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00125-011-2401-4","volume":"55","author":"L Serrano-Marco","year":"2012","unstructured":"Serrano-Marco L, Barroso E, El Kochairi I, et al. The peroxisome proliferator-activated receptor (PPAR) beta\/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia. 2012;55:743\u201351.","journal-title":"Diabetologia."},{"issue":"1","key":"430_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u201339.","journal-title":"J Am Soc Echocardiogr."},{"issue":"1","key":"430_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCIMAGING.111.971143","volume":"5","author":"B Pitt","year":"2012","unstructured":"Pitt B, Zannad F. The detection of myocardial fibrosis: an opportunity to reduce cardiovascular risk in patients with diabetes mellitus? Circ Cardiovasc Imaging. 2012;5(1):9\u201311.","journal-title":"Circ Cardiovasc Imaging."},{"issue":"1","key":"430_CR21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2013.03.009","volume":"139","author":"GV Halade","year":"2013","unstructured":"Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013;139(1):32\u201340.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"430_CR22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/jpet.111.179697","volume":"339","author":"S Oyamada","year":"2011","unstructured":"Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia\/reperfusion. J Pharmacol Exp Ther. 2011;339(1):143\u201351.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"430_CR23","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.ijcard.2013.07.150","volume":"168","author":"X Palomer","year":"2013","unstructured":"Palomer X, Salvado L, Barroso E, Vazquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol. 2013;168(4):3160\u201372.","journal-title":"Int J Cardiol"},{"issue":"5","key":"430_CR24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2013.157","volume":"37","author":"D Mikami","year":"2014","unstructured":"Mikami D, Kimura H, Kamiyama K, et al. Telmisartan activates endogenous peroxisome proliferator-activated receptor-delta and may have anti-fibrotic effects in human mesangial cells. Hypertens Res. 2014;37(5):422\u201331.","journal-title":"Hypertens Res"},{"issue":"7","key":"430_CR25","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1582-4934.2010.01085.x","volume":"15","author":"X Feng","year":"2011","unstructured":"Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta\/AMPK pathway. J Cell Mol Med. 2011;15(7):1572\u201381.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"430_CR26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/db12-0570","volume":"62","author":"L Li","year":"2013","unstructured":"Li L, Luo Z, Yu H, et al. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-delta activation. Diabetes. 2013;62(3):762\u201374.","journal-title":"Diabetes"},{"issue":"7","key":"430_CR27","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2337\/db10-0704","volume":"60","author":"L Serrano-Marco","year":"2011","unstructured":"Serrano-Marco L, Rodriguez-Calvo R, El Kochairi I, et al. Activation of peroxisome proliferator-activated receptor-beta\/-delta (PPAR-beta\/-delta) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes. 2011;60(7):1990\u20139.","journal-title":"Diabetes"},{"issue":"3","key":"430_CR28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/diabetes.55.03.06.db05-0934","volume":"55","author":"JT Cheng","year":"2006","unstructured":"Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes. 2006;55(3):819\u201325.","journal-title":"Diabetes"},{"issue":"2","key":"430_CR29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cardiores.2005.10.019","volume":"69","author":"M Pesant","year":"2006","unstructured":"Pesant M, Sueur S, Dutartre P, et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res. 2006;69(2):440\u20139.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"430_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cvr\/cvu034","volume":"102","author":"A Haghikia","year":"2014","unstructured":"Haghikia A, Ricke-Hoch M, Stapel B, Gorst I, Hilfiker-Kleiner D. STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovasc Res. 2014;102(2):281\u20139.","journal-title":"Cardiovasc Res"},{"issue":"22","key":"430_CR31","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1073\/pnas.2134694100","volume":"100","author":"JJ Jacoby","year":"2003","unstructured":"Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 2003;100(22):12929\u201334.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"430_CR32","doi-asserted-by":"crossref","first-page":"H1941","DOI":"10.1152\/ajpheart.00338.2011","volume":"301","author":"Y Li","year":"2011","unstructured":"Li Y, Zhang H, Liao W, et al. Transactivated EGFR mediates alpha(1)-AR-induced STAT3 activation and cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2011;301(5):H1941\u201351.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"430_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/db12-0337","volume":"62","author":"F Mashili","year":"2013","unstructured":"Mashili F, Chibalin AV, Krook A, Zierath JR. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2013;62(2):457\u201365.","journal-title":"Diabetes"},{"issue":"3","key":"430_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00395-015-0486-5","volume":"110","author":"A Das","year":"2015","unstructured":"Das A, Salloum FN, Filippone SM, et al. Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Basic Res Cardiol. 2015;110(3):31.","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"430_CR35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin ii receptor antagonist with selective ppargamma-modulating activity. Hypertension. 2004;43(5):993\u20131002.","journal-title":"Hypertension"},{"issue":"9","key":"430_CR36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.hjh.0000242405.68461.84","volume":"24","author":"J Janke","year":"2006","unstructured":"Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24(9):1809\u201316.","journal-title":"J Hypertens"},{"issue":"2","key":"430_CR37","doi-asserted-by":"crossref","first-page":"e000103","DOI":"10.1161\/JAHA.113.000103","volume":"2","author":"H Kusunoki","year":"2013","unstructured":"Kusunoki H, Taniyama Y, Rakugi H, Morishita R. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorgamma-hepatocyte growth factor pathway independent of angiotensin ii type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc. 2013;2(2):e000103.","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"430_CR38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/FJC.0b013e3182592d7b","volume":"60","author":"A Nagashima","year":"2012","unstructured":"Nagashima A, Watanabe R, Ogawa M, et al. Different roles of PPAR-\u03b3 activity on physiological and pathological alteration after myocardial ischemia. J Cardiovasc Pharmacol. 2012;60(2):158\u201364.","journal-title":"J Cardiovasc Pharmacol"},{"key":"430_CR39","first-page":"2198645","volume":"2016","author":"HJ Liu","year":"2016","unstructured":"Liu HJ, Liao HH, Yang Z, Tang QZ. Peroxisome proliferator-activated receptor-\u03b3 is critical to cardiac fibrosis. PPAR Res. 2016;2016:2198645.","journal-title":"PPAR Res"},{"key":"430_CR40","doi-asserted-by":"crossref","first-page":"628628","DOI":"10.1155\/2013\/628628","volume":"2013","author":"J Be\u0142towski","year":"2013","unstructured":"Be\u0142towski J, Racha\u0144czyk J, W\u0142odarczyk M. Thiazolidinedione-induced\u00a0fluid\u00a0retention:\u00a0recent\u00a0insights\u00a0into the\u00a0molecular\u00a0mechanisms. PPAR Res. 2013;2013:628628.","journal-title":"PPAR Res."},{"key":"430_CR41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1475-2840-12-133","volume":"12","author":"H Li","year":"2013","unstructured":"Li H, Liu Z, Wang J, et al. Susceptibility to\u00a0myocardial\u00a0ischemia reperfusion\u00a0injury\u00a0at early stage of type 1 diabetes in rats. Cardiovasc Diabetol. 2013;12:133.","journal-title":"Cardiovasc Diabetol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-016-0430-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:35:56Z","timestamp":1498322156000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-016-0430-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1186\/s12933-016-0430-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]},"article-number":"113"}}